TP53 and cancer: Moreover, over-expression of BCL-2 (or other pro-survival BCL-2 proteins) renders both malignant as well as non-transformed cells markedly resistant to diverse anti-cancer agents that kill cells in either a TP53-dependent [144] or TP53-independent manner [145].